home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2812.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
46 lines
Document 2812
DOCN M94A2812
TI Use of DNCB as a immune modulator in HIV positive patients--a pilot
study.
DT 9412
AU Traub A; Irmandade da Santa Casa de Misericordia de Porto Alegre,
Brazil.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):219 (abstract no. PB0304). Unique
Identifier : AIDSLINE ICA10/94369763
AB OBJECTIVE: To evaluate the efficacy of topical DNCB application in
patients with early HIV disease. METHODS: This study was performed in a
public hospital where patients are routinely seen free of charge.
Patients of both genders were included in the sample. All forms of
transmissions were included as well. Inclusion criteria were (1) HIV
seropositivity with CD4 T cells counts between 100 and 600
cells/microliters, (2) no previous use of DNCB either no current use of
antiretroviral therapy. Application of DNCB was initiated with a 2%
acetone solution. If no sensitization were accomplished, a DNCB in a 10%
solution was applied, repeated weekly until a positive response were
obtained. After that maintenance weekly application of a 2% or 1% DNCB
solution was applied. Usually the solution was applied to a 3.0 cm2 in
the forearm. Until the present were followed 14 patients, 8 men and 6
women for a average period of 10 months. Clinical evaluation were
performed every three weeks. Peripheral blood lymphocytes subsets were
analyzed each 6 weeks, using monoclonal antibodies and flow cytometry,
including helper/inducer T cells (CD4) and suppressor/cytotoxic T cells
(CD8). RESULTS: (1) None of the patients developed opportunistic
infection or malignancy. (2) All patients have gain weight. (3) CD4
counts remained stable or had a slight increase. (3) CD8 counts had a
significant increase. No side effects other than mild eczema were found.
CONCLUSION: Considering the low cost, the convenience of the easy
application and the good results found until the present date, we
suggest that this drug can be useful for the treatment of HIV early
infection. We acknowledge that comparative studies must be done to prove
the real efficacy of the DNCB use.
DE Adjuvants, Immunologic/ADMINISTRATION & DOSAGE/PHARMACOLOGY/
*THERAPEUTIC USE Administration, Cutaneous
Dinitrochlorobenzene/ADMINISTRATION & DOSAGE/PHARMACOLOGY/ *THERAPEUTIC
USE Drug Evaluation Female Human HIV Infections/*THERAPY Immunity,
Cellular/DRUG EFFECTS Male Treatment Outcome Weight Gain/DRUG EFFECTS
MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).